Your browser doesn't support javascript.
loading
Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Parikh, Sameer A; Keating, Michael J; O'Brien, Susan; Wang, Xuemei; Ferrajoli, Alessandra; Faderl, Stefan; Burger, Jan; Koller, Charles; Estrov, Zeev; Badoux, Xavier; Lerner, Susan; Wierda, William G.
Affiliation
  • Parikh SA; Departments of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Blood ; 118(8): 2062-8, 2011 Aug 25.
Article in En | MEDLINE | ID: mdl-21750315
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Antibodies, Monoclonal Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 2011 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Antibodies, Monoclonal Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 2011 Type: Article Affiliation country: United States